Chinese Biomedical CRO Biocytogen Raises $77M In Series D Round

News Source: China Money Network.

Biocytogen, a biomedical contract research organization (CRO) specialized in gene-targeted animal models and services, announced on Thursday that it has raised RMB543 million (US$77.11 million) in a series D round of financing.

Continue Reading the Entire Article Here >>

This news article comes via China Money Network, who is the copyright owner of this information and news. has licensed the rights to this article and any republication or re-distribution in whole or in part of this content is strictly prohibited without the express consent of

You May Also Like